DrugPatentWatch Database Preview
Ariad Company Profile
Email this page to a colleague
See Plans and PricingWhat is the competitive landscape for ARIAD, and when can generic versions of ARIAD drugs launch?
ARIAD has two approved drugs.
There are seven US patents protecting ARIAD drugs.
There are one hundred and twenty-four patent family members on ARIAD drugs in thirty-two countries and twenty-five supplementary protection certificates in fifteen countries.
Summary for Ariad
| International Patents: | 124 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Ariad: | See patent lawsuits for Ariad |
Drugs and US Patents for Ariad
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | 10,385,078 | Start Trial | Y | Y | Start Trial | ||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | 9,273,077 | Start Trial | Start Trial | ||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | 9,611,283 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ariad Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014093579 | Start Trial |
| Japan | 2016503010 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007133562 | Start Trial |
| Singapore | 11201702980Q | Start Trial |
| South Korea | 101436303 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ariad Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1973545 | 72/2013 | Austria | Start Trial | PRODUCT NAME: PONATINIB; REGISTRATION NO/DATE: EU/1/13/839 20130701 |
| 1973545 | C20130033 00093 | Estonia | Start Trial | PRODUCT NAME: PONATINIIB;REG NO/DATE: K(2013)4238 (LOPLIK) 01.07.2013 |
| 1973545 | CA 2013 00066 | Denmark | Start Trial | PRODUCT NAME: POATINIB, HERUNDER PONATINIB HYDROCHLORID; REG. NO/DATE: EU/1/13/839/001-004 20130701 |
| 1973545 | 2013/059 | Ireland | Start Trial | PRODUCT NAME: PONATINIB IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701 |
| 1973545 | 490 | Finland | Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
